ALPHA DIAGNOSTIC INTERNATIONAL

Product Specification Sheet

Marburg virus glycoprotein (MARV GP) Antibodies

☐ **Cat #** MVGP12-A Rabbit Anti-Marburg virus glycoprotein peptide (Muskoe MARV GP) IgG, aff pure **SIZE**: 100 ul

Ebola virus (EBOV, formerly Zaire ebolavirus**)** causes severe disease in humans and in nonhuman primates in the form of viral hemorrhagic fever.. Zaire ebolavirus is a virological taxon included in the genus Ebolavirus, family Filoviridae, order Mononegavirales. The species has a single virus member, Ebola virus (EBOV). **Ebolavirus species Zaire** (ZEBOV) causes highly lethal hemorrhagic fever, resulting in the death of **~90%** of patients within days. Most information on immune responses to ZEBOV comes from in vitro studies and animal models. Ebola Zaire attacks every organ and tissue in the human body except skeletal muscle and bone. Ebola is classified as a **Level 4** pathogen (higher than AIDS) with a 2 to 21 day (7 to 14 days average) incubation period. There are currently **five** known strains of Ebola: **Bundibugyo, Zaire, Sudan, Reston and Tai**. All cause illness in sub-human primates. Only Ebola Reston does not cause illness in humans. The mortality rate of Ebola victims is between 60% and 90%; with Ebola Sudan at 60% and Ebola Zaire at 90%.

The virions are tubular in general form but variable in overall shape and may appear as the classic shepherd's crook or eyebolt. Ebola virions consist of 7 structural proteins. At the center is the helical **ribonucleocapsid,** which consists of the genomic RNA wrapped around a polymer of **nucleoproteins (NP**). Associated with the ribonucleoprotein is the RNA-dependent **RNA polymerase (L)** with the **polymerase cofactor (VP35)** and a **transcription activator (VP30).** The ribonucleoprotein is embedded in a matrix, formed by the major (VP40) and minor (VP24) matrix proteins. They are surrounded by a **lipid membrane** derived from the host cell membrane. The membrane anchors a glycoprotein (GP1,2) that projects 7 to 10 nm spikes away from its surface. While nearly identical to **Marburg virions** in structure, Ebola virions are antigenically distinct.



The most common diagnostic methods are RT-PCR in conjunction with antigen-capture ELISA which can be performed in field or mobile hospitals and laboratories. There are currently no FDA-approved vaccines for the prevention of EVD. The most promising ones are DNA vaccines or are based on adenoviruses, vesicular **stomatitis Indiana virus (VSIV) or filovirus-like particles (VLPs**) as all of these candidates could protect nonhuman primates from Ebola virus-induced disease. DNA vaccines, adenovirus-based vaccines, and VSIV-based vaccines have entered clinical trials.

Source of Antigen and Antibodies

Antigen	A peptide sequence to Marburg virus (MARV) glycoprotein 2 (GP2) subunit.
Ab Host/type	Rabbit, Polyclonal IgG Aff. pure (Cat# MVGP12-A). Supplied n PBS, PH 7.4, 0.1% BSA with 0.01% sodium azide as preservative.
2-Ab	Goat Anti-rabbit IgG-HRP cat # 20320 (AP, biotin, FITC conjugates)
-ve control IgG	#20009-1, Rabbit (non-immune) IgG, purified, suitable for ELISA, Western, IHC as –ve control

Form & Storage of Antibodies/Peptide Control

Antibodies

☐ 100 ul ☐ solution ☐ lyophilized powder

Buffer: PBS+0.01% azide

Reconstitute powder 100 ul of PBS.

Storage

Short-term: unopened, undiluted vials for less than a week at 4oC.

Long-term: at –20°C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

Stability: 6-12 months at –20°C or below.
Shipping: 4°C for solutions and room temp for powder.

Recommended Usage

Western Blotting: An initial dilution of 1:200-2K is recommended for Western.

ELISA: 1:1K-100K; using 50-100 ng antigen/well.

Histochemistry & Immunofluorescence: not tested.

Specificity & Cross-reactivity:
The antibody reacts with glycoprotein region of Marburg virus VLPs and recombinant MARV GP and free GP2 subunit. No cross reactivity to Sudan Ebolavirus (SEBOV) GP, Zaire Ebolavirus (ZEBOV) GP was observed. Antibodies and recombinant GP proteins from various Ebola and Marburg viruses (Angola #MVGP15-R-10 and Muskoe #MVGP16-R10) are available for control studies.

References: Thomas W (2010) Archives of Virology 155 (12): 2083–103. Taylor D (2010) BMC Evolutionary Biology 10: 193. Feldmann H (2005) . A. Virus Taxonomy—Eighth Report of the International Committee on Taxonomy of Viruses. 645–653. Adam M (2010) Emerg Infect Dis 16(12):1969-72

*This product is for In vitro research use only.

Related material available from ADI

http://www.4adi.com/objects/catalog/product/extras/Ebola_Marburg_Vaccines_ELISA_Flr.pdf

EVGP11-A	Anti-Ebola virus glycoprotein (Recombinant) IgG, purified
EVGP11-C	Rec. (sf9) Zaire-Ebola virus glycoprotein protein control WB
EVGP15-A	Anti-Zaire Ebola virus glycoprotein (GP, 1-676aa/DNA vaccine) IgG,
EVGP16-A	Anti-Zaire Ebola virus glycoprotein (GP 1-652aa/DNA vaccine) IgG,
EVGP16-R-10	Rec. (sf9) Sudan-Ebola virus glycoprotein (minus transmembrane domain, his-tag, 68 kda), purified
EVGP17-R-10	Recombinant (sf9) Zaire-Ebola virus glycoprotein (minus transmembrane domain, his-tag, 68 kda), purified
EVNP13-A	Anti-Zaire-Ebola virus nucleoprotein (EBOV NP, 1-739/DNA vaccine) IgG,
EVP401-A	Anti-Zaire-Ebola virus VP40 peptide (EBOV VP40) IgG,
EVP401-C	Rec. Zaire-Ebola virus VP40 protein control for Western
EVP405-R-10	Rec. (E.coli) Zaire-Ebola virus VP40
AE-320520-1	Human Anti-Ebola virus Nucleoprotein (NP) IgG ELISA Kit,
AE-320530-1	Human Anti-Ebola virus Nucleoprotein (NP) IgM ELISA Kit
AE-320620-1	Human Anti-Zaire-Ebola virus glycoprotein (GP) IgG ELISA
AE-320720-1	Human Anti-Zaire-Ebola virus VP40 IgG ELISA Kit,
AE-320730-1	Human Anti-Zaire-Ebola virus VP40 IgM ELISA Kit,
AE-320800-48	Human Zaire-Ebola Virus antigen ELISA Kit, 48 tests,
AE-320800-96	Human Zaire-Ebola Virus antigen ELISA Kit, 96 tests,

MVGP12-A 140927A

Alpha Diagnostic Intl Inc., 6203 Woodlake Center Dr, San Antonio, TX 78244, USA; **Email**: service@4adi.com
☎ (800) 786-5777; (210) 561-9515; **Fax**: (210) 561-9544; **Web Site**: www.4adi.com